EGFRvIII as a promising target for antibody-based brain tumor therapy.

被引:48
|
作者
Kuan C.T. [1 ]
Wikstrand C.J. [1 ]
Bigner D.D. [1 ]
机构
[1] Department of Pathology, Duke University Medical Center, Durham, 27710, NC
关键词
EGFRvIII; Glioma; Immunotherapy;
D O I
10.1007/BF02482738
中图分类号
学科分类号
摘要
Cell surface receptors are attractive candidates for targeted therapy of cancer. Growth factors and their receptors play important roles in the regulation of cell division, development, and differentiation. Among those, the epidermal growth factor receptor (EGFR) was the first identified to be amplified and/or rearranged in malignant gliomas. The most common rearranged form, EGFR type III variant (EGFRvIII), has a deletion in its extracellular domain that results in the formation of a new, tumor-specific target found in glioblastoma multiforme, as well as in breast, ovarian, prostate, and lung carcinomas. Monoclonal antibodies have been developed with specific activity against this mutant receptor. These antibodies are internalized into the cell after receptor binding. Specific antibodies, either unarmed or armed with cytotoxic agents, including radioisotopes and toxins, have shown a promising role for EGFRvIII as a target for brain tumor therapy.
引用
收藏
页码:71 / 78
页数:7
相关论文
共 50 条
  • [31] Monoclonal antibody-based therapy of neuroblastoma
    Cheung, NKV
    Kushner, BH
    Kramer, K
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2001, 15 (05) : 853 - +
  • [32] Affinity and Avidity in Antibody-Based Tumor Targeting
    Rudnick, Stephen I.
    Adams, Gregory P.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2009, 24 (02) : 155 - 161
  • [33] Podoplanin is a novel antibody-based therapeutic target for glioblastoma
    Kato, Yukinari
    Mishima, Kazuhiko
    Kaneko, Mika
    Zalutsky, Michael
    Kuan, Chien-Tsun
    Bigner, Darell
    CANCER RESEARCH, 2009, 69
  • [34] Cripto: A novel target for antibody-based cancer immunotherapy
    Xing, PX
    Hu, XF
    Pietersz, GA
    Hosick, HL
    McKenzie, IFC
    CANCER RESEARCH, 2004, 64 (11) : 4018 - 4023
  • [35] Minimal residual cancer:: A target for antibody-based strategies
    Riethmüller, G
    Kufer, P
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 358 (01) : R197 - R197
  • [36] Antibody-based therapy targeting tumor vascular endothelial cells suppresses solid tumor growth in rats
    Ohizumi, I
    Tsunoda, S
    Taniguchi, K
    Saito, H
    Esaki, K
    Makimoto, H
    Wakai, Y
    Tsutsumi, Y
    Nakagawa, S
    Utoguchi, N
    Kaiho, S
    Ohsugi, Y
    Mayumi, T
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 236 (02) : 493 - 496
  • [37] Antibody-Based Imaging and Therapy for Precision Medicine
    Wei, Weijun
    Jiang, Dawei
    Evangelista, Laura
    Cai, Weibo
    MOLECULAR PHARMACEUTICS, 2022, 19 (10) : 3453 - 3455
  • [38] The Multicompartmental p32/gClqR as a New Target for Antibody-based Tumor Targeting Strategies
    Sanchez-Martin, David
    Cuesta, Angel M.
    Fogal, Valentina
    Ruoslahti, Erkki
    Alvarez-Vallina, Luis
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (07) : 5197 - 5203
  • [39] Isotype selection for antibody-based cancer therapy
    Vukovic, N.
    van Elsas, A.
    Verbeek, J. S.
    Zaiss, D. M. W.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2021, 203 (03): : 351 - 365
  • [40] Antibody-Based Immunotoxins for Colorectal Cancer Therapy
    Sanz, Laura
    Ibanez-Perez, Raquel
    Guerrero-Ochoa, Patricia
    Lacadena, Javier
    Anel, Alberto
    BIOMEDICINES, 2021, 9 (11)